Virus-Immunotherapy combo targets Hard-to-Treat colorectal cancer
NCT ID NCT07411781
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a combination of a specially modified virus (PIN) and an immunotherapy drug (sintilimab) in about 25 adults with advanced colorectal cancer that has spread to the liver and has not responded to at least two prior treatments. The main goals are to check the safety of the combination and see if it can shrink tumors. Participants must be between 18 and 75 years old and have a specific type of colorectal cancer called pMMR/MSS.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?